Paclitaxel Injection Market Size is Forecasted to Hit US$ 11.16 Billion by 2030

Canada – The paclitaxel injection market was valued at 4.51 billion USD in 2021 and is forecasted to reach around US$ 11.16 billion by 2030, growing at a robust CAGR of 12.5% during the forecast period 2021 to 2030. The report contains 150+ pages with detailed analysis

The global paclitaxel injection market is primarily driven by the surging prevalence of cancer across the globe. The rising consumption of tobacco, alcohol, rising prevalence of smoking, and various other factors contributes towards the growth in the number of cancer cases across the globe. According to GLOBOCAN 2020, a report on cancer produced by the International Agency for Research on Cancer, there were around 19.3 million new cases of cancer and around 10 million cancer death were recorded in the year 2020.

The global burden of cancer is estimated to reach 28.4 million cases by 2040, which will be a 47% rise in the cases of cancer recorded in 2020. Therefore, the demand for the paclitaxel injection is expected to witness a rapid surge during the forecast period. The paclitaxel injection is used in chemotherapy that restricts the growth of the cancer cells in the human body. The paclitaxel injection offers improved efficiency as compared to other medications used in the treatment of cancer.

Paclitaxel Injection Market Estimations Y-O-Y:

• Market Size Was Valued In 2021: US$ 4.51 Billion
• Market Size Is Projected to Grow By 2022: US$ 4.97 Billion
• Market Size Is Projected to Grow By 2023: US$ 5.49 Billion
• Market Size Is Projected to Grow By 2024: US$ 6.06 Billion
• Market Size Is Projected to Grow By 2025: US$ 6.7 Billion
• Market Size Is Projected to Grow By 2026: US$ 7.41 Billion
• Market Size Is Projected to Grow By 2027: US$ 8.2 Billion
• Market Size Is Projected to Grow By 2028: US$ 9.08 Billion
• Market Size Is Projected to Grow By 2029: US$ 10.06 Billion
• Market Size Is Projected to Grow By 2030: US$ 11.16 Billion
• Compound Annual Growth Rate (CAGR) from 2022 to 2030: 12.5 percent

COVID-19 Impact Analysis:

• The cancer patients has a high risks of getting infected with the cOVID-19 infection. The immune system of the cancer patient is weak and this may present a high risk to the patients
• The supply chain disruptions and the difficulties in the procurement of raw materials had adversely affected the production of the paclitaxel injection

Key Developments in the Marketplace:

• In March 2019, Celgene Corporation announced updates for ABRAXANE for the treatment of pancreatic cancer and metastatic triple-negative breast cancer at the initial phase.
• In December 2019, Sun Pharma Advanced Research Company Ltd. announced that Abraxis Bioscience had withdrawn its claims regarding infringement overpaclitaxel injection concentration for suspension.

Scope of the Paclitaxel Injection Market

Report Highlights:

• Based on the indication, the breast cancer segment was the most dominant segment in the global paclitaxel injection market in 2020. This growth is attributed to the increased prevalence of the breast cancer among the female population. According to the International Agency for Research on Cancer, breast cancer has surpassed the lungs cancer as the most diagnosed type of cancer. Furthermore, breast cancer accounted for around 11.7% of the new cancer cases in 2020. Therefore, the growing cases of breast cancer and rising awareness regarding the availability of the paclitaxel injection for the treatment of breast cancer is expected to sustain the dominance of this segment throughout the forecast period.

• Depending on the end user, the hospitals was the leading segment in 2020. The hospitals are well-equipped with various advanced and digital technologies that facilitates in the diagnosis and treatment of different types of cancer. The availability of the paclitaxel injection in stock and the increased penetration of the hospitals across the globe has boosted the growth of this segment in the past years.

• North America was the dominant paclitaxel injection market in 2020. North America is characterized by the increased prevalence of cancer. According to the Cancer.org, there were around 1.8 million new cancer cases estimated in US and around 606,520 cancer deaths in 2020. The presence of improved and advanced healthcare infrastructure, increased healthcare expenditure, and the high awareness regarding the availability of advanced treatments and medicines like paclitaxel injection has propelled the growth of the North America paclitaxel injection market.

• Asia Pacific is estimated to be the most opportunistic market. Asia Pacific is witnessing an increasing prevalence of cancer owing to rising prevalence of smoking and increasing tobacco consumption. The rising healthcare expenditure and rising investments in the development of healthcare infrastructure are some of the major factors that are facilitating the growth of the Asia Pacific paclitaxel injection market. The rising penetration of the multispecialty hospitals in the emerging markets like India, China, and South Korea is expected to have a positive and significant impact on the Asia Pacific paclitaxel injection market.

Key Players:

The paclitaxel injection market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the paclitaxel injection market include:

• Celgene Corporation
• Sagent Pharmaceuticals
• Abbott Laboratories
• Bristol Myers Squibb
• Fresenius Kabi Oncology Ltd
• Luye Pharma Group
• Onco Therapies Ltd (Strides Arcolab Ltd.)
• NOVASEP
• Pfizer

Market Segmentation

By Indication

• Prostate Cancer
• Breast Cancer
• Non-Small Cell Lung Cancer
• AIDS related Kaposi’s Sarcoma
• Ovarian Cancer
• Stomach Cancer
• Cervical Cancer
• Esophageal Cancer
• Testicular Cancer
• Lung Cancer
• Pancreatic Cancer
• Others

By End User

• Cancer Research Centers
• Hospital
• Others

Regional Segmentation

• North America (U.S. and Canada)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Find More Press Releases at https://www.globenewswire.com/en/search/organization/Precedence%2520Researchv

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Paclitaxel Injection Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Paclitaxel Injection Market

5.1. Covid-19: Paclitaxel Injection Industry Impact
5.2. Paclitaxel Injection Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Paclitaxel Injection Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Paclitaxel Injection Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Paclitaxel Injection Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing incidence of cancer worldwide
6.1.1.2. Better efficiency of paclitaxel over other preparations in cancer treatment
6.1.2. Market Restraints
6.1.2.1. High cost
6.1.3. Market Opportunities
6.1.3.1. Growing incidence of cancer worldwide
6.1.3.2. Better efficiency of paclitaxel over other preparations in cancer treatment

Chapter 7. Global Paclitaxel Injection Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Paclitaxel InjectionMarket Revenue by Market Players (2017 -2021)
7.1.1.2. Paclitaxel InjectionMarket Revenue Market Share by Market Players (2017 -2021)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Paclitaxel Injection Market, By Indication

8.1. Paclitaxel Injection Market, by Indication, 2017-2030
8.1.1. Prostate Cancer
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Non-Small Cell Lung Cancer
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. AIDS related Kaposi’s Sarcoma
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Ovarian Cancer
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Stomach Cancer
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Cervical Cancer
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Esophageal Cancer
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Testicular Cancer
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Lung Cancer
8.1.10.1. Market Revenue and Forecast (2017-2030)
8.1.11. Pancreatic Cancer
8.1.11.1. Market Revenue and Forecast (2017-2030)
8.1.12. Others
8.1.12.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Paclitaxel Injection Market, By End User

9.1. Paclitaxel Injection Market, by End User, 2017-2030
9.1.1. Cancer Research Centers
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Hospital
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Other End Users
9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Paclitaxel Injection Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue Forecast by Indication (2017-2030)
10.1.2. Market Revenue Forecast by End User (2017-2030)
10.1.3. U.S
10.1.3.1. Market Revenue Forecast (2017-2030)
10.1.4. Canada
10.1.4.1. Market Revenue Forecast (2017-2030)
10.2. Europe
10.2.1. Market Revenue Forecast by Indication (2017-2030)
10.2.2. Market Revenue Forecast by End User (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue Forecast (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue Forecast (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue Forecast (2017-2030)
10.2.6. Rest of EU
10.2.6.1. Market Revenue Forecast (2017-2030)
10.3. Asia Pacific (APAC)
10.3.1. Market Revenue Forecast by Indication (2017-2030)
10.3.2. Market Revenue Forecast by End User (2017-2030)
10.3.3. China
10.3.3.1. Market Revenue Forecast (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue Forecast (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue Forecast (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue Forecast (2017-2030)
10.4. LATAM
10.4.1. Market Revenue Forecast by Indication (2017-2030)
10.4.2. Market Revenue Forecast by End User (2017-2030)
10.4.3. Brazil
10.4.3.1. Market Revenue Forecast (2017-2030)
10.4.4. Rest of LATAM
10.4.4.1. Market Revenue Forecast (2017-2030)
10.5. Middle East and Africa (MEA)
10.5.1. Market Revenue Forecast by Indication (2017-2030)
10.5.2. Market Revenue Forecast by End User (2017-2030)
10.5.3. GCC
10.5.3.1. Market Revenue Forecast (2017-2030)
10.5.4. North Africa
10.5.4.1. Market Revenue Forecast (2017-2030)
10.5.5. South Africa
10.5.5.1. Market Revenue Forecast (2017-2030)
10.5.6. Rest of MEA
10.5.6.1. Market Revenue Forecast (2017-2030)

Chapter 11. Company Profiles

11.1. Celgene Corporation
11.1.1. Company Overview, Business Information, Regional Presence
11.1.2. Product Portfolio Analysis
11.1.2.1. Product Details, Specification, Indication
11.1.3. Revenue, Price, and Gross Margin (2015-2020)
11.1.4. Recent Developments and Strategies
11.2. Sagent Pharmaceuticals
11.2.1. Company Overview, Business Information, Regional Presence
11.2.2. Product Portfolio Analysis
11.2.2.1. Product Details, Specification, Indication
11.2.3. Revenue, Price, and Gross Margin (2015-2020)
11.2.4. Recent Developments and Strategies
11.3. Abbott Laboratories
11.3.1. Company Overview, Business Information, Regional Presence
11.3.2. Product Portfolio Analysis
11.3.2.1. Product Details, Specification, Indication
11.3.3. Revenue, Price, and Gross Margin (2015-2020)
11.3.4. Recent Developments and Strategies
11.4. Bristol Myers Squibb
11.4.1. Company Overview, Business Information, Regional Presence
11.4.2. Product Portfolio Analysis
11.4.2.1. Product Details, Specification, Indication
11.4.3. Revenue, Price, and Gross Margin (2015-2020)
11.4.4. Recent Developments and Strategies
11.5. Fresenius Kabi Oncology Ltd
11.5.1. Company Overview, Business Information, Regional Presence
11.5.2. Product Portfolio Analysis
11.5.2.1. Product Details, Specification, Indication
11.5.3. Revenue, Price, and Gross Margin (2015-2020)
11.5.4. Recent Developments and Strategies
11.6. Luye Pharma Group
11.6.1. Company Overview, Business Information, Regional Presence
11.6.2. Product Portfolio Analysis
11.6.2.1. Product Details, Specification, Indication
11.6.3. Revenue, Price, and Gross Margin (2015-2020)
11.6.4. Recent Developments and Strategies
11.7. Onco Therapies Ltd (Strides Arcolab Ltd.)
11.7.1. Company Overview, Business Information, Regional Presence
11.7.2. Product Portfolio Analysis
11.7.2.1. Product Details, Specification, Indication
11.7.3. Revenue, Price, and Gross Margin (2015-2020)
11.7.4. Recent Developments and Strategies
11.8. NOVASEP
11.8.1. Company Overview, Business Information, Regional Presence
11.8.2. Product Portfolio Analysis
11.8.2.1. Product Details, Specification, Indication
11.8.3. Revenue, Price, and Gross Margin (2015-2020)
11.8.4. Recent Developments and Strategies
11.9. Pfizer
11.9.1. Company Overview, Business Information, Regional Presence
11.9.2. Product Portfolio Analysis
11.9.2.1. Product Details, Specification, Indication
11.9.3. Revenue, Price, and Gross Margin (2015-2020)
11.9.4. Recent Developments and Strategies

Chapter 12. Appendix

12.1. About Us
12.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333